Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jochen Utikal
Selma Ugurel

Showing results (201-210 of 490) with videos related to

Pageof 49
Sort By:
Frontiers in Immunology|March 20, 2018
Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced ImmunosuppressionViktor Fleming, Xiaoying Hu, Rebekka Weber, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 5, 2016
Nebenwirkungsmanagement bei Immun-Checkpoint-Blockade durch CTLA-4- und PD1-Antikörper beim metastasierten MelanomKatharina C Kähler, Jessica C Hassel, Lucie Heinzerling, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 5, 2016
Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanomaKatharina C Kähler, Jessica C Hassel, Lucie Heinzerling, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|May 17, 2022
8. Virtuelles Netzwerktreffen der zertifizierten Hautkrebszentren 21.01.2022Frank Meiß, Thomas K Eigentler, Margit Huber, et al.
Journal of Carcinogenesis|July 18, 2008
BRAFV600E mutations in malignant melanoma are associated with increased expressions of BAALCDavid Schrama, Gunhild Keller, Roland Houben, et al.
Journal of Cutaneous Pathology|September 16, 2006
Cutaneous leiomyosarcoma with myxoid alteration arising in a setting of multiple cutaneous smooth muscle neoplasmsJochen Utikal, Georg Haus, Nina Poenitz, et al.
Cellular Immunology|December 9, 2020
IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapyRebekka Weber, Christopher Groth, Samantha Lasser, et al.
Oncoimmunology|August 18, 2023
Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCsAlisa Lepper, Rebekka Bitsch, Feyza Gül Özbay Kurt, et al.
International Journal of Molecular Sciences|September 4, 2020
Myeloid Cell Modulation by Tumor-Derived Extracellular VesiclesIhor Arkhypov, Samantha Lasser, Vera Petrova, et al.
The British Journal of Dermatology|February 20, 2026
Melanoma of unknown primary shows oncogenic pattern and clinical course of sun-exposed melanomaGeorg Lodde, Jonida Dollani, Wolfgang Galetzka, et al.
Pageof 49

Showing results (201-210 of 490) with videos related to

Sort By:
Pageof 49
Frontiers in Immunology|March 20, 2018
Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced ImmunosuppressionViktor Fleming, Xiaoying Hu, Rebekka Weber, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 5, 2016
Nebenwirkungsmanagement bei Immun-Checkpoint-Blockade durch CTLA-4- und PD1-Antikörper beim metastasierten MelanomKatharina C Kähler, Jessica C Hassel, Lucie Heinzerling, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 5, 2016
Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanomaKatharina C Kähler, Jessica C Hassel, Lucie Heinzerling, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|May 17, 2022
8. Virtuelles Netzwerktreffen der zertifizierten Hautkrebszentren 21.01.2022Frank Meiß, Thomas K Eigentler, Margit Huber, et al.
Journal of Carcinogenesis|July 18, 2008
BRAFV600E mutations in malignant melanoma are associated with increased expressions of BAALCDavid Schrama, Gunhild Keller, Roland Houben, et al.
Journal of Cutaneous Pathology|September 16, 2006
Cutaneous leiomyosarcoma with myxoid alteration arising in a setting of multiple cutaneous smooth muscle neoplasmsJochen Utikal, Georg Haus, Nina Poenitz, et al.
Cellular Immunology|December 9, 2020
IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapyRebekka Weber, Christopher Groth, Samantha Lasser, et al.
Oncoimmunology|August 18, 2023
Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCsAlisa Lepper, Rebekka Bitsch, Feyza Gül Özbay Kurt, et al.
International Journal of Molecular Sciences|September 4, 2020
Myeloid Cell Modulation by Tumor-Derived Extracellular VesiclesIhor Arkhypov, Samantha Lasser, Vera Petrova, et al.
The British Journal of Dermatology|February 20, 2026
Melanoma of unknown primary shows oncogenic pattern and clinical course of sun-exposed melanomaGeorg Lodde, Jonida Dollani, Wolfgang Galetzka, et al.
Pageof 49